PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Medetomidine Withdrawal in Philadelphia: Health Alert Guidance, Not Trial Evidence

medetomidinexylazinefentanylmethadonehydromorphoneclonidinedexmedetomidinealpha-2 agonistopioid withdrawalhealth alerttoxicologyemergency departmentPhiladelphia Emergency Medicine / Toxicology

Background Information

Opioid withdrawal complaints soar as MOUD provision drops in EDs.

Increases in opioid withdrawal complaints and decreased medication for opioid use disorder (MOUD) provision in emergency departments (EDs) indicate shifts in withdrawal management due to adulterants. Withdrawal complaints rose from 16.2% to 42.7%, while ED MOUD receipt fell from 46.8% to 27.9% during the study. While the findings highlight increasing withdrawal complaints, the retrospective nature limits applicability to adjust current ED protocols. EDs face rising withdrawal cases; strategies may need reevaluation.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: London KS, Warrick-Stone T, Cherney A, McGann S, Durney P, Goodstein D, Weinstein LC, Randolph F

Citation: London KS, Warrick-Stone T, Cherney A, et al. Emergency Department Opioid Withdrawal Management Across the Alpha-2 Agonist Adulterated Fentanyl Era in Philadelphia, PA: A Multi-Site Study. Substance use & addiction journal. 2026:29767342261459988. doi:10.1177/29767342261459988

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.